BioXcel Therapeutics, Inc. 8-K

What Happened
BioXcel Therapeutics (BTAI) filed an 8-K reporting that it completed a registered direct offering that closed on March 11, 2026, raising approximately $7.8 million in gross proceeds. Under a Purchase Agreement dated March 10, 2026, the company sold 2,480,294 shares of common stock with accompanying warrants and pre-funded warrants to purchase up to 2,020,491 shares, with combined offering prices of $1.739 per share+accompanying warrant and $1.738 for the pre-funded-warrant package. The accompanying warrants are immediately exercisable at $1.614 per share and expire five years after issuance. The filing also discloses a Warrant Amendment Agreement (dated March 10, 2026) that reduced the exercise price and extended the term of certain outstanding warrants held by the purchaser.

Key Details

• Offering closed: March 11, 2026; Purchase Agreement dated March 10, 2026.
• Gross proceeds: approximately $7.8 million (before placement agent fees and expenses).
• Securities issued: 2,480,294 common shares with accompanying warrants; pre-funded warrants to purchase up to 2,020,491 shares (combined prices $1.739 and $1.738).
• Accompanying warrants: $1.614 exercise price, immediately exercisable, 5-year term.
• Warrant amendment: exercise price for certain existing warrants (1,385,083 shares) reduced to $1.614 and term extended to five years; purchaser paid ~$173,135 for this amendment.
• Placement agent: Rodman & Renshaw LLC; cash fee 6% of gross proceeds and warrants equal to 4.0% of shares placed (180,031 shares) at $2.0175 exercise price (125% of offering price), five-year term; reimbursable expenses up to $75,000 plus up to $15,950 for clearing/closing.

Why It Matters
This transaction provides BioXcel with near-term cash (~$7.8M) to support operations or development programs. However, the offering and multiple classes of warrants (including placement agent warrants and amended lower‑priced warrants) create potential future dilution if warrants are exercised. Investors should note the relatively low warrant exercise price ($1.614) and the five‑year exercise windows, which increase the likelihood these instruments could convert into additional shares over time. The company documented the legal opinion supporting the issuance and described customary agreement terms (representations, indemnities, closing conditions).